Abstract: 【Abstract】Objective To explore the cardiovascular outcomes with sacubitril-valsartan in patients undergoing hemodialysis. Methods 13 maintenance hemodialysis (MHD) patients from Peking University People's Hospital were selected, without obvious edema, severe infection or acute cardiovascular events recently. Blood pressure and echocardiography of the patients were recorded. Paired-Samples T test was used to identify the effects of sacubitril-valsartan in MHD patients. Results ①A total of 13 patients on MHD for 99 (14～155) months (8 males and 5 females) were included in this study. ②Compared with baseline levels, left ventricular ejection fractions (LVEF) (43.0 ± 10.2% vs. 60.0 ± 13.9%, t =- 4.769, P＜0.001) were markedly improved after treatment with sacubitril-valsartan. ③ Compared with baseline levels, NT-proBNP levels (25594pg/ml vs. 15325 pg/ml, t = 2.979, P = 0.012) were markedly decreased after treatment with sacubitril-valsartan. ④No serious adverse events occurred. Conclusions Sacubitril-valsartan is effective and safe for MHD patients.

Key words: Hemodialysis, Sacubitril-Valsartan, Cardiac function, Bioelectrical impedance analysis